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Abstract
Background
This intercontinental study aimed to study gram-negative rod (GNR) resistance in
hematopoietic stem cell transplantation (HSCT).
Methods
GNR bacteremias occurring during 6 months post-HSCT (February 2014–May 2015)
were prospectively collected, and analyzed for rates and risk factors for resistance to
fluoroquinolones, noncarbapenem anti-Pseudomonas β-lactams (noncarbapenems),
carbapenems, and multidrug resistance.
Results
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Issue Section:  Major Article
Sixty-five HSCT centers from 25 countries in Europe, Australia, and Asia reported
data on 655 GNR episodes and 704 pathogens in 591 patients (Enterobacteriaceae,
73%; nonfermentative rods, 24%; and 3% others). Half of GNRs were
fluoroquinolone and noncarbapenem resistant; 18.5% carbapenem resistant; 35.2%
multidrug resistant. The total resistance rates were higher in allogeneic HSCT (allo-
HSCT) vs autologous HSCT (auto-HSCT) patients (P < .001) but similar in
community-acquired infections. Noncarbapenem resistance and multidrug
resistance were higher in auto-HSCT patients in centers providing vs not providing
fluoroquinolone prophylaxis (P < .01). Resistance rates were higher in southeast vs
northwest Europe and similar in children and adults, excluding higher
fluoroquinolone- and β-lactam/β-lactamase inhibitor resistance rates in allo-HSCT
adults. Non-Klebsiella Enterobacteriaceae were rarely carbapenem resistant.
Multivariable analysis revealed resistance risk factors in allo-HSCT patients:
fluoroquinolone resistance: adult, prolonged neutropenia, breakthrough on
fluoroquinolones; noncarbapenem resistance: hospital-acquired infection,
breakthrough on noncarbapenems or other antibiotics (excluding fluoroquinolones,
noncarbapenems, carbapenems), donor type; carbapenem resistance: breakthrough
on carbapenem, longer hospitalization, intensive care unit, previous other antibiotic
therapy; multidrug resistance: longer hospitalization, breakthrough on β-lactam/β-
lactamase inhibitors, and carbapenems. Inappropriate empiric therapy and mortality
were significantly more common in infections caused by resistant bacteria.
Conclusions
Our data question the recommendation for fluoroquinolone prophylaxis and call for
reassessment of local empiric antibiotic protocols. Knowledge of pathogen-specific
resistance enables early appropriate empiric therapy. Monitoring of resistance is
crucial.
Hematopoietic stem cell transplantation (HSCT) is increasingly used to cure a wide
range of malignant and nonmalignant disorders [1]. Growing antimicrobial
resistance, especially among gram-negative rods (GNRs), negatively affects
prognosis and can influence eligibility for HSCT [2]. Treatment options remain
limited [3], although the proportion of GNRs among infectious etiologies is rising
[4–6] and resistant GNR infections are associated with delay in giving appropriate
therapy, increased mortality, and high risk of infection recurrence [7–9]. Several
studies, mainly limited to single centers or countries, describe rates and risk factors
for specific resistant pathogens, such as extended-spectrum β-lactamase (ESBL)–
producing Enterobacteriaceae or multidrug-resistant (MDR) bacteria in patients
with cancer and HSCT recipients [10–13]. The majority, however, were performed in
countries with high resistance rates in both the hospitalized and general
populations [12–14]. The risk of infection is influenced by local factors, among them
prevalence of resistance, prophylactic practices, empiric treatment, and
antimicrobial stewardship. Only a handful of studies focus on children and
autologous HSCT (auto-HSCT) patients [12, 15, 16]. This study aimed to describe
resistance rates and risk factors in GNR bacteremia in HSCT patients, based on large
intercontinental data.
METHODS
Study Design and Data Collection
This was a noninterventional prospective study. All patients in whom allogeneic
HSCT (allo-HSCT) or auto-HSCT was performed during February 2014–May 2015 in
the participating centers were included. Data on GNR bacteremia episodes that
occurred from the initiation of the conditioning regimen until 6 months after the
HSCT were reported, including pathogen and its antimicrobial susceptibility,
presence of risk factors, and mortality. This study was performed in accordance
with the appropriate regulations in the participating countries including approval by
the ethical committees as required, and registered at ClinicalTrials.gov
(NTC02257931).
The primary endpoint was to determine the proportion of GNRs resistant to (1) one
of noncarbapenem anti-Pseudomonas β-lactams (noncarbapenems), including
ceftazidime or cefepime or β-lactam/β-lactamase inhibitors (βL/βLIs); (2)
carbapenems (one of meropenem/imipenem/doripenem); (3) one of
fluoroquinolones; (4) MDR pathogens.
The secondary endpoints were to determine (1) proportion of GNRs resistant to
other antibiotics; and (2) risk factors for resistant GNRs, as defined in the primary
endpoints.
Microbiological Workup
Guidelines used to determine isolates’ susceptibility were by the European
Committee for Antimicrobial Susceptibility Testing in 41 (64.1%) laboratories, the
Clinical and Laboratory Standards Institute in 19 (29.7%) laboratories, and others in
4 (6.2%) laboratories. Resistance to antibiotics was studied by in vitro sensitivity
tests in the local laboratories using disk diffusion in 46 of 64 (71.9%) and/or
minimum inhibitory concentration determination in 60 of 64 (93.8%) centers.
Pathogens with intermediate susceptibility to antibiotics were considered resistant.
Definitions
An MDR GNR was defined as bacteria resistant to ≥1 agent in ≥3 of the following
categories: (1) broad-spectrum cephalosporins (ceftazidime or cefepime); (2) anti-
Pseudomonas βL/βLIs; (3) carbapenems; (4) aminoglycosides; (5) fluoroquinolones.
All Stenotrophomonas maltophilia strains were considered MDR. Extensively drug-
resistant (XDR) bacteria defined if checked for susceptibility to all relevant
antimicrobials and found nonsusceptible to ≥1 agent in all but ≤2 categories [17].
Infections occurring >48 hours since the hospitalization were considered hospital
acquired.
Neutropenia was defined as an absolute neutrophil count <500 cells/μL.
Breakthrough bacteremia was defined as bacteremia developing during antibiotic
treatment (including fluoroquinolone prophylaxis) provided for ≥48 hours before
obtaining the blood culture.
Geographic regions [4] included Northwest (Austria, Belgium, Denmark, Finland,
France, Germany, Netherlands, Sweden, Switzerland, United Kingdom); Southeast
(Croatia, Cyprus, Czech Republic, Greece, Israel, Italy, Lithuania, Poland, Portugal,
Russia, Slovakia, Spain, Turkey); other countries (Australia, China).
Statistical Analysis
The main characteristics of patients were reported by descriptive statistics on the
total of the available information.
The incidence of resistance was computed as a percentage, the denominator being
the number of GNR pathogens and the numerator being the number of pathogens
classified as “resistant.” Early mortality was computed as a percentage of death
occurred within 7 days after bacteremia on the episodes with a follow-up available
at the same time.
The relationship between resistance and the following risk factors was investigated:
Background: sex, age at HSCT, underlying disease, myeloablative conditioning,
fluoroquinolone prophylaxis.
At the time of bacteremia: time since HSCT, duration of neutropenia, neutrophil
recovery, duration of hospitalization, hospital-acquired infection, breakthrough
bacteremia, graft-vs-host disease (GVHD), acute GVHD grade II–IV, veno-
occlusive disease.
Before bacteremia, within 1 month: urinary catheter, ≥2 weeks of steroids, and/or
other immunosuppressive treatment; within 3 months: any hospitalization,
hospitalization in the intensive care unit (ICU), any bacteremia, previous
antibiotic therapy, and number of antibiotic classes.
Differences between groups were tested using linear or logistic regression models,
using the generalized estimating equation method to take into account the
dependence of observations nested by patient and center [18]. The same models
were used to study all relationships between resistance and characteristics or
prognostic factors. Variables showing significance from the univariate model
entered a multivariable model. The results obtained from these analyses are
considered as exploratory and hypothesis-generating.
A P value <.05 was considered statistically significant. All P values are 2 sided. All
the analyses were performed using the statistical software SAS version 9.4 (SAS
Institute, Cary, North Carolina).
RESULTS
Patients and Episodes
Sixty-five HSCT centers from 25 countries reported data on 655 GNR episodes in
591 patients (1.1 episodes [range, 1–4] per patient) (Supplementary Table 1).
Characteristics of the background patients and episodes are presented in Tables 1
and 2. Median time to develop GNR bacteremia was 8 (range, –15 to 183) days after
HSCT. Fluoroquinolone prophylaxis was provided in 34 of 45 (75.6%) allo-HSCT and
22 of 49 (44.9%) auto-HSCT adult centers, and in 6 of 24 (25.0%) allo-HSCT and 2
of 23 (8.7%) auto-HSCT pediatric centers.
Table 1.
Patient Characteristics (N = 591)
Characteristic No. (%) 
Age, y, median (range) 50.9 (0.3–72.9) 
Children (<18 y) 79 (13.4) 
Male sex 357 (60.4) 
Underlying disease 
 Acute leukemia 212 (35.9) 
 Lymphoma 148 (25.0) 
 Plasma cell disorders 109 (18.4) 
 Myelodysplastic/myeloproliferative syndromes 54 (9.1) 
 Chronic leukemia 8 (1.4) 
 Solid tumor 12 (2.0) 
 Nonmalignant disease 48 (8.1) 
Time since diagnosis of the underlying disease until HSCT, mo, median (range) 10.4 (1.0–256.2) 
Allogeneic HSCT 360 (60.9) 
Donor (allogeneic HSCT) 
 Unrelated 175 (48.9) 
 Matched related 114 (31.8) 
 Mismatched related 69 (19.3) 
Stem cell source 
 Peripheral blood 451 (76.4) 
 Bone marrow 101 (17.1) 
 Both bone marrow and peripheral blood 10 (1.7) 
 Umbilical cord blood 28 (4.7) 
Conditioning (allogeneic HSCT) 
 Myeloablative 241 (68.1) 
 Nonmyeloablative 113 (31.9) 
Karnofsky score, median (range) 90 (0–100) 
Disease status after HSCT 
 Continued complete remission 317 (75.1) 
 Never in complete remission 79 (18.7) 
 Partial remission/stable disease 26 (6.2) 
Graft-vs-host disease prophylaxis before bacteremia (allogeneic HSCT) 
 Total provided 339 
 Cyclosporine/tacrolimus alone 51 (15.0) 
 Cyclosporine/tacrolimus + methotrexate 136 (40.1) 
 Cyclosporine/tacrolimus + MMF or prednisone 117 (34.5) 
 Other 35 (10.3) 
Graft manipulation ex vivo (including T-cell depletion) 31 (6.2) 
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: HSCT, hematopoietic stem cell transplantation; MMF, mycophenolate mofetil.
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Table 2.
Episode Characteristics
Characteristic Transplant Type Total
(N =
655) 
P
Value 
Allogeneic
(n = 414) 
Autologous
(n = 241) 
Neutropenia at the time of episode <500 cells/
μL 
296 (71.5) 199 (82.9) 495
(75.7) 
.005 
Neutropenia at the time of episode <100 cells/
μL 
259 (73.4) 175 (77.8) 434
(75.1) 
.4 
Duration of neutropenia <500 cells/μL, d,
median (range) 
7 (1–246) 2.5 (1–124) 5 (1–
246) 
<.0001 
Duration of neutropenia <500 cells/μL <7 d,
median (range) 
153 (37.0) 189 (78.8) 342
(52.3) 
<.0001 
Duration of neutropenia <100 cells/μL, d,
median (range) 
5 (1–80) 2 (1–28) 3 (1–
80) 
<.0001 
Duration of neutropenia <100 cells/μL <7 d 176 (49.9) 171 (76.0) 347
(60.0) 
<.0001 
Absolute neutrophil count recovered before
bacteremia 
147 (39.9) 24 (10.8) 171
(28.9) 
<.0001 
Previous hospitalization 255 (64.6) 121 (50.4) 376
(59.2) 
.001 
Number of hospitalization days during 3 mo
preceding bacteremia, median (range) 
38 (1–186) 15 (1–94) 30 (1–
186) 
<.0001 
Duration of current hospitalization before
episode, d, median (range) 
17 (0–266) 11 (0–87) 14 (0–
266) 
<.0001 
Hospital-acquired bacteremia 355 (86.8) 215 (90.7) 570
(88.2) 
.08 
Previous ICU hospitalization 28 (6.9) 4 (1.7) 32
(4.9) 
.01 
Bacteremia developed during hospitalization
in the ICU 
17 (4.2) 0 (0.0) 17
(2.6) 
… 
Breakthrough bacteremia 303 (73.4) 98 (40.7) 401
(61.3) 
<.0001 
 Cephalosporins  30 (7.3) 8 (3.3) 38
(5.8) 
.04 
 Anti-Pseudomonas βL/βLIs 65 (15.7) 16 (6.6) 81
(12.4) 
.001 
 Carbapenems  54 (13.1) 7 (2.9) 61
(9.3) 
<.0001 
 Any β-lactam  159 (38.5) 36 (14.9) 195
(29.8) 
<.0001 
 Fluoroquinolones 118 (28.6) 50 (20.7) 168
(25.7) 
.03 
 Aminoglycosides 22 (5.3) 5 (2.1) 27
(4.1) 
.04 
 Others  79 (19.1) 13 (5.4) 92
(14.1) 
<.0001 
Previous antibiotic therapy 309 (77.3) 104 (44.4) 413
(65.1) 
<.0001 
 Cephalosporins  46 (11.5) 8 (3.4) 54 .001 
a
b
c
d
a
(8.5) 
 Anti-Pseudomonas βL/βLIs 88 (22.0) 17 (7.3) 105
(16.6) 
<.0001 
 Carbapenems  86 (21.5) 10 (4.3) 96
(15.1) 
<.0001 
 Any β-lactam  198 (49.5) 42 (17.9) 240
(37.9) 
<.0001 
 Fluoroquinolones 121 (30.3) 45 (19.2) 166
(26.2) 
.003 
 Aminoglycosides 30 (7.5) 5 (2.1) 35
(5.5) 
.007 
 Others  101 (25.3) 12 (5.1) 113
(17.8) 
<.0001 
No. of antibiotic classes of previous antibiotic
therapy  
    
 1 antibiotic class 86 (21.4) 36 (15.3) 122
(19.2) 
<.0001 
 2 classes 73 (18.2) 24 (10.2) 97
(15.2) 
 
 ≥3 antibiotic categories 131 (32.6) 18 (7.7) 149
(23.4) 
 
GVHD at the time of bacteremia (% of all allo-
HSCT) 
71 (17.3)   … 
Acute GVHD at the time of bacteremia (% of all
allo-HSCT) 
62 (15.1)   … 
Grade II–IV of acute GVHD before bacteremia
(% of all allo-HSCT) 
12 (4.5)   … 
Chronic GVHD (% of all allo-HSCT) 9 (2)   … 
Veno-occlusive disease at the time of
bacteremia 
12 (2.9) 3 (1.3) 15
(2.3) 
.2 
b
c
d
e
Urinary catheter 38 (9.5) 7 (2.9) 45
(7.0) 
.007 
Previous bacteremia 127 (30.7) 24 (9.9) 151
(23.1) 
<.0001 
Recent immunosuppression 335 (81.1) 57 (23.8) 392
(60.1) 
<.0001 
Recent steroid treatment 142 (34.5) 53 (22.3) 195
(30.0) 
.008 
Time since HSCT, d, median (range) 11 (–15 to
183) 
7 (–8 to
177) 
8 (–15
to 183) 
<.0001 
Central line infection 138 (38.4) 73 (32.3) 211
(36.1) 
.1 
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: allo, allogeneic; auto, autologous; βL/βLI, β-lactam/β-lactamase inhibitor; GVHD, graft-vs-
host disease; HSCT, hematopoietic stem cell transplant; ICU, intensive care unit.
Cephalosporins: ceftazidime, cefepime, ceftriaxone, cefotaxime, cefuroxime, cefazolin.
Carbapenems: meropenem, imipenem, ertapenem, doripenem.
Any β-lactam: either cephalosporin, anti-Pseudomonas βL/βLI, carbapenem, or any other β-lactam
antibiotic.
Others: any antibiotics, excluding any β-lactam, fluoroquinolones, aminoglycosides, and prophylactic
use of trimethoprim-sulfamethoxazole or dapsone.
Previous antibiotic exposure to the following antibiotic classes was reported: (a) any cephalosporins; (b)
anti-Pseudomonas βL/βLIs; (c) carbapenems (meropenem, imipenem, ertapenem, doripenem); (d)
fluoroquinolones (either treatment and prophylaxis); (e) aminoglycosides; (f) macrolides; (g) anti–gram-
positives (glycopeptides, linezolid, daptomycin); (h) antianaerobes (metronidazole, clindamycin); (i) colistin;
(j) tigecycline; (k) aztreonam; (l) other antibiotics.
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Microbiological Results
Seven hundred four GNRs included Enterobacteriaceae (514 [73%]),
a
b
c
d
e
nonfermentative rods (167 [24%]), and others (23 [3%]) (Figure 1). Five hundred
forty-six (83.4%) episodes were monomicrobial and 109 (16.6%) polymicrobial,
including GNRs only (47 [7.2%]) or together with other pathogens (62 [9.5%]).
Resistance Rates
Half of GNRs were resistant to fluoroquinolones and to noncarbapenems, 18.5%
were carbapenem resistant, and 35.2% were MDR (Table 3). One of 73 (1.4%)
Pseudomonas aeruginosa and 4 of 14 (28.6%) Acinetobacter species were XDR.
Resistance rates to other antibiotics are presented in Table 3.
Table 3.
Figure 1.
View large Download slide
Distribution of gram-negative pathogens. Other Enterobacteriaceae include Enterobacter spp (n = 41),
Klebsiella spp (n = 24), Citrobacter spp (n = 12), Serratia spp (n = 6), Proteus spp (n = 3), Raoultella spp (n = 1).
Other nonfermentative rods include Acinetobacter spp (n = 17), 1 each of Sphingomonas paucimobilis,
Shewanella putrefaciens, Sphingobacterium multivorum, Comamonas testosterone, Ochrobactrum spp,
Ralstonia pickettii, Paracoccus yeei, Achromobacter xylosoxidans. Other gram-negative rods include
Capnocytophaga spp (n = 8), Moraxella spp (n = 4), Aeromonas spp (n = 3), Campylobacter spp (n = 2),
Rhizobium radiobacter (n = 2), and 1 each of Salmonella enteritidis, Haemophilus influenzae, Burkholderia
cepacia, Elizabethkingia meningoseptica.
Antibiotic Resistance Rates in Gram-Negative Rods: Total, According to Transplant Type, and in Children
Versus Adults
Data are presented as no./No. (%). The following differences were significant: the resistance rates to
fluoroquinolones, noncarbapenems, carbapenems, and multidrug resistance were significantly higher in
 Resistance to 
Total
Isolates 
GNRs
in Allo-
HSCT 
GNRs
in
Auto-
HSCT 
GNRs in
Allo-
HSCT
Adults 
GNRs in
Allo-
HSCT
Children 
GNRs
in
Auto-
HSCT
Adults 
GNRs in
Auto-
HSCT
Children 
Primary endpoints 
 Fluoroquinolone 325/645
(50.4) 
227/408
(55.6)* 
98/237
(41.4)* 
205/326
(62.9)** 
22/82
(26.8)** 
95/228
(41.7) 
3/9
(33.3) 
 Noncarbapenem
β-lactam 
322/632
(50.9) 
241/407
(59.2)* 
81/225
(36.0)* 
199/322
(61.8) 
42/85
(49.4) 
78/214
(36.4) 
3/11
(27.3) 
 Carbapenem 127/688
(18.5) 
105/443
(23.7)* 
22/245
(8.9)* 
80/349
(22.9) 
25/94
(26.6) 
20/234
(8.6) 
2/11
(18.2) 
 Multidrug
resistant 
236/671
(35.2) 
187/428
(43.7)* 
49/243
(20.2)* 
149/334
(44.6) 
38/94
(40.4) 
46/231
(19.9) 
3/12
(25.0) 
Secondary endpoints 
 Anti-
Pseudomonas
cephalosporin 
255/656
(38.9) 
199/416
(47.8) 
56/240
(23.3) 
160/332
(48.2) 
39/84
(46.4) 
55/229
(24.0) 
1/11
(9.1) 
 Anti-
Pseudomonas βL/
βLI 
230/627
(36.7) 
177/399
(44.4) 
53/228
(23.2) 
146/310
(47.1)*** 
31/89
(34.8)*** 
51/217
(23.5) 
2/11
(18.2) 
 Aminoglycoside 216/662
(32.6) 
162/422
(38.4) 
54/240
(22.5) 
135/335
(40.3) 
27/87
(31.0) 
51/228
(22.4) 
3/12
(25.0) 
 Colistin 22/358
(6.1) 
18/250
(7.2) 
4/108
(3.7) 
12/205
(5.9) 
6/45
(13.3) 
4/102
(3.9) 
0/6 (0.0) 
 Tigecycline 15/182
(8.2) 
12/124
(9.7) 
3/58
(5.2) 
10/109
(9.2) 
2/15
(13.3) 
3/58
(5.2) 
Not
checked 
GNRs isolated in allogeneic HSCT vs autologous HSCT recipients (*P < .001 for all). The rate of resistance to
fluoroquinolones and anti-Pseudomonas βL/βLIs was significantly higher in adults vs children following
allogeneic HSCT (**P < .0001 and ***P = .048, respectively).
Abbreviations: allo, allogeneic; auto, autologous; βL/βLI, β-lactam/β-lactamase inhibitor; GNR, gram-
negative rod; HSCT, hematopoietic stem cell transplantation.
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There was no strong correlation between the rates of GNR bacteremia and resistance
to noncarbapenems and carbapenems per country; and no correlation between
fluoroquinolone resistance and bacteremia rate per center (Supplementary Figure
1A–C).
Resistance Rates According to Pathogens
Fluoroquinolone resistance was significantly more frequent among
Enterobacteriaceae (57.2% vs 30.7%; P < .0001); carbapenem resistance (50.9% vs
8.4%; P < .0001), and multidrug resistance (46.6% vs 31.9%; P = .001) in
nonfermentative rods (Table 4).
Table 4.
Resistance Rates According to Pathogens
Pathogens Resistance to 
Fluoro-
quinolones 
Noncarbapenem
β-Lactams 
Carbapenem Multidrug
Resistant 
Aminoglycoside 
Escherichia coli 185/283
(65.4) 
140/281 (49.8) 7/301 (2.3) 81/290
(27.9) 
96/298 (32.2) 
Klebsiella
pneumoniae 
71/111
(63.9) 
79/118 (66.9) 31/124 (25.0) 63/121
(52.1) 
53/124 (42.7) 
Enterobacter spp 8/39 (20.5) 19/39 (48.7) 3/41 (7.3) 9/39
(23.1) 
8/41 (19.5) 
Other
Enterobacteriaceae 
7/41 (17.1) 9/43 (20.9) 2/45 (4.4) 5/44
(11.4) 
8/45 (17.8) 
a
Data are presented as no./No. (%).
Significant differences between Enterobacteriaceae and nonfermentative rods (P < .0001).
Significant differences between Enterobacteriaceae and nonfermentative rods (P = .001).
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Six of 31 (19%) S. maltophilia isolates were resistant to trimethoprim-
sulfamethoxazole.
One-third of noncarbapenem-resistant, and half of MDR pathogens, were
carbapenem resistant (Supplementary Table 2). Six of 33 (18.2%) carbapenem-
resistant P. aeruginosa isolates were susceptible to both cephalosporins and βL/βLIs
(Supplementary Table 3); 1 of 29 (3.5%) was colistin resistant.
Among carbapenem-resistant Enterobacteriaceae, 15 of 41 (36.6%) were resistant to
amikacin, 16 of 41 (39.0%) to gentamicin, 4 of 41 (9.8%) to both aminoglycosides;
32 of 40 (78%) to fluoroquinolones, 5 of 17 (29.4%) to tigecycline, and 6 of 33
(18.2%) to colistin.
Resistance Rate According to Hematopoietic Stem Cell Transplantation Type
Total
Enterobacteriaceae 
271/474
(57.2)  
247/481 (51.4) 43/511 (8.4)  158/494
(31.9)  
165/508 (32.5) 
Pseudomonas
aeruginosa 
29/96 (30.2) 33/92 (35.9) 36/95 (37.9) 28/96
(29.2) 
26/97 (26.8) 
Acinetobacter
baumannii 
7/10 (70.0) 8/10 (80.0) 7/11 (63.6) 7/11
(63.6) 
5/11 (45.5) 
Stenotrophomonas
maltophilia 
6/22 (27.3) 14/16 (87.5) 34/34 (100) 34/34
(100) 
9/9 (100) 
Other
nonfermentative
rods 
4/22 (18.2) 13/20 (65.0) 5/21 (23.8) 7/22
(31.8) 
5/23 (21.7) 
Total
nonfermentative
rods 
46/150
(30.7)  
68/138 (49.3) 82/161
(50.9)  
76/163
(46.6)  
45/140 (32.1) 
a
a
b
a a b
a
b
The resistance rates to fluoroquinolones (55.6% vs 41.4%), noncarbapenems (59.2%
vs 36.0%), carbapenems (23.7% vs 8.9%), and multidrug resistance (43.7% vs
20.2%) were higher in GNRs isolated in allo-HSCT vs auto-HSCT recipients (P <
.001 for all) (Table 3). Among community-acquired infections, there were no
significant differences in fluoroquinolone resistance (38.8% vs 63.2%),
noncarbapenem resistance (42.0% vs 42.1%), carbapenem resistance (15.1% vs
18.2%), and multidrug resistance (28.3% vs 19%) between allo-HSCT and auto-
HSCT patients (Supplementary Tables 4 and 5).
Resistance Rate in Children Versus Adults
Similar resistance rates were observed in children and adults. Only the resistance
rate to fluoroquinolones and βL/βLIs was significantly higher in adults compared
with children following allo-HSCT (P < .0001 and P = .048, respectively) (Table 3);
the difference was significant in southeast countries only.
Geographical Distribution of Resistance Rates
There was a wide distribution in the resistance rates between countries
(Supplementary Table 6). Resistance rates were more frequent in the southeast vs
northwest European region: for noncarbapenems (266/481 [55.3%] vs 32/116
[27.6%], P < .0001); fluoroquinolones (270/496 [54.4%] vs 44/121 [36.4%]; P =
.002); carbapenems (109/526 [20.7%] vs 6/123 [4.9%]; P < .0001); and multidrug
resistance (201/514 [39.1%] vs 16/118 [13.6%]; P < .0001).
Risk Factors for Resistance
Univariate analysis of risk factors for resistant GNRs in allo-HSCT and auto-HSCT
recipients is presented in Supplementary Tables 4 and 5. Multivariable analysis was
possible in allo-HSCT patients only (Table 5), as rate of resistance was low in auto-
HSCT patients.
Table 5.
Multivariate Analysis of Risk Factors for Resistance in Gram-Negative Rods in Allogeneic Transplant Patients
Risk Factor Fluoroquinolone-
Resistant GNRs 
Noncarbapenem
β-Lactam-
Carbapenem-
Resistant GNRs 
Multidrug-
Resistant GNRs 
Resistant GNRs 
OR
(95%
CI) 
P
Value 
OR
(95%
CI) 
P
Value 
OR
(95%
CI) 
P
Value 
OR
(95%
CI) 
P
Value 
Duration of
neutropenia (≥7
d) 
1.79
(1.10–
2.91) 
.02  NS  NS  NS 
Breakthrough
bacteremia on
fluoroquinolones 
7.26
(3.84–
13.72) 
<.0001  NS  NS  NS 
Age (adults) 3.87
(2.07–
7.25) 
<.0001  NS  NS  NS 
Hospital-
acquired
infection 
 NS 2.09
(1.08–
4.03) 
.029  NS  NS 
Breakthrough
bacteremia on
βL/βLI 
 NS 2.45
(1.14–
5.23) 
.02  NS 2.30
(1.20–
4.41) 
.013 
Breakthrough
bacteremia on
cephalosporins 
 NS 6.36
(1.68–
24.07) 
.01  NS  NS 
Previous
antibiotic
therapy with
other
antibiotics  
 NS 2.59
(1.30–
5.15) 
.007 2.07
(1.15–
3.73) 
.016  NS 
Longer duration
of current
hospitalization
before episode 
 NS  NS 1.01
(1.00–
1.02) 
.041 1.01
(1.00–
1.03) 
.032 
Current
bacteremia
developed during
hospitalization in
the ICU 
 NS  NS 3.92
(1.18–
3.03) 
.026  NS 
Breakthrough  NS  NS 9.08 <.0001 3.49 <.0001 
a
Abbreviation: βL/βLI, anti-Pseudomonas β-lactam β-lactamase inhibitor; CI, confidence interval; GNR, gram-
negative rod; ICU, intensive care unit; NS, not significant; OR, odds ratio.
Other antibiotics: any antibiotic therapy excluding β-lactams, fluoroquinolones, aminoglycosides.
View Large
To study the association between fluoroquinolone prophylaxis and resistance, we
compared resistance rates in GNRs cultured during the period when prophylaxis is
provided (in neutropenic patients without empiric or targeted antibiotics therapy),
in centers that do and do not provide prophylaxis.
The rate of fluoroquinolone-resistant GNRs was higher in centers providing
prophylaxis (79% vs 50%, P = .001 in allo-HSCT; 74% vs 25%, P < .001 in auto-
HSCT). The rate of noncarbapenem-resistant (36% vs 13%; P = .002) and MDR (35%
vs 8%; P < .001) bacteria was higher in auto-HSCT patients in centers providing
prophylaxis (Supplementary Table 7).
Outcome
The 7-day mortality was 38 of 589 (6.5%). The mortality according to resistance
pattern was 9% vs 2% (P = .002) in episodes caused by noncarbapenem resistant vs
sensitive GNRs; 18% vs 4% (P < .001) in those carbapenem resistant vs sensitive;
and 11% vs 4% (P = .002) in MDR vs non-MDR. Inappropriate empiric therapy was
provided for 124 of 586 (21.2%) GNRs; being 101 of 270 (37.4%) for noncarbapenem
resistant vs 12 of 274 (4.4%) noncarbapenem susceptible bacteria; 62 of 97 (63.9%)
for carbapenem resistant vs 61 of 481 (12.7%) carbapenem susceptible; and 91 of 197
(46.2%) for MDR vs 30 of 368 (8.1%) non-MDR GNRs (P < .001 for all).
Breakthrough
bacteremia on
carbapenems 
 NS  NS 9.08
(4.57–
18.02) 
<.0001 3.49
(1.96–
6.21) 
<.0001 
Matched related
vs matched
unrelated donor 
 NS 1.82
(1.05–
3.14) 
.01  NS  NS 
Mismatched vs
matched
unrelated donor 
  2.29
(1.21–
4.35) 
     
a
DISCUSSION
In this study, we demonstrate antimicrobial susceptibility patterns among GNRs
causing bacteremia in HSCT patients, and geographical distribution of resistance in
25 countries from Europe, Asia, and Australia. We compare allo- and auto-HSCT
recipients, and children and adults; and analyze risk factors for antibiotic
resistance.
The emerging resistance challenges antibacterial prophylaxis policy and
complicates empiric and targeted treatment choices. Benefit of fluoroquinolone
prophylaxis was demonstrated in a country with a baseline resistance of
approximately 20% in GNRs from the community and medical departments [19, 20].
In our study, 39% of GNRs causing community-acquired infections in allo-HSCT
and 63% in auto-HSCT were fluoroquinolone resistant (Supplementary Tables 4 and
5). High rates of fluoroquinolone resistance may be the price to pay for lower rates
of bacteremia in centers providing prophylaxis. We could not, however, demonstrate
correlation between the rates of bacteremia and fluoroquinolone resistance
(Supplementary Figure 1A). Doubts regarding the benefits of fluoroquinolone
prophylaxis are accompanied by concern about increased rates of resistance to other
antibiotics following exposure to fluoroquinolones. No association between
fluoroquinolone prophylaxis and the increase in MDR bacteria was shown in the
meta-analysis of studies published up to 2005 [21]. Later published studies,
however, correlated exposure to fluoroquinolones with increase in infections
resulting from fluoroquinolone-resistant, ESBL-producing, carbapenem-resistant,
and MDR pathogens [14, 22, 23]. In our study, in auto-HSCT patients, treatment in
centers providing fluoroquinolone prophylaxis, breakthrough on fluoroquinolones,
and previous exposure to fluoroquinolones (Supplementary Tables 5 and 7) were
associated with resistance to noncarbapenems and MDR. The risk could, however,
be influenced by other factors, as outpatient vs inpatient transplantation setting,
which were not reported in our study. The benefits and potential risks of
fluoroquinolone prophylaxis must be carefully assessed, especially in centers with
high fluoroquinolone resistance rates among GNRs [24].
Empiric treatment with noncarbapenem β-lactams, or even carbapenems [25], can
be inappropriate in centers with high resistance rates to these antibiotics and lead
to increased mortality [2, 13]. In our study, approximately 40% of community-
acquired infections were resistant to noncarbapenems and 15%–18% to
carbapenems (Supplementary Tables 4 and 5), probably due to acquisition of
resistant bacteria during previous hospitalizations. This can lead to inappropriate
empiric therapy. Carbapenem treatment increases the chance of providing
appropriate empiric therapy, especially in southeast European countries. In centers
with low rate of noncarbapenem resistance at the onset of febrile neutropenia,
noncarbapenems, however, can still be a good option. Universal recommendations
for empiric therapy are tricky because of significant geographical variations.
Practical decisions on empiric therapy must be based on continuously updated data
concerning local resistance patterns and bacteremia rates [26]. We are thus unable
to recommend the specific resistance rate threshold that indicates change in the
empiric therapy protocol as our study was not designed to answer this question.
While the proportion of resistant bacteria was high in some centers, its impact on
patient outcome can be low if GNR bacteremia is rare (Supplementary Figures 1B
and 1C).
Resistance to multiple antibiotics complicates the targeted therapy choice.
Susceptibility to tigecycline, polymyxins, fosfomycin, and aminoglycosides must be
promptly reported in the centers with carbapenem-resistant infections, as some
bacteria were resistant to these last-resort antibiotics in our and other studies [8,
27]. Eighteen percent of carbapenem-resistant P. aeruginosa was susceptible to both
cephalosporins and βL/βLIs in our study and, in contrast to carbapenem-resistant
Enterobacteriaceae, can be treated with these agents, especially administered as
high-dose prolonged infusion [28].
Knowledge of pathogen-specific resistance patterns can help direct appropriate
empiric therapy following rapid bacterial identification by matrix-assisted laser
desorption/ionization–time of flight (MALDI-TOF), prior to susceptibility results.
Carbapenem monotherapy should be appropriate on identification of non–Klebsiella
pneumoniae Enterobacteriaceae, which are usually carbapenem susceptible. A
carbapenem/colistin with or without aminoglycoside combination should, however,
be considered for K. pneumoniae or Acinetobacter pending susceptibility results, as a
significant proportion of them are carbapenem resistant. Streamlining of antibiotic
therapy, of course, should be performed when susceptibilities are available.
Data on resistance rates in post-HSCT children are scarce [12, 16, 29]. Surprisingly,
resistance rates were mostly similar in children and in adults in our study. This
differs from the lower resistance rates in children vs adults reported in a literature
review of studies published until 2011 [4]. Resistance rates in a retrospective
multicenter US study (2004–2014) in pediatric allo-HSCT recipients [16] are also
lower than in our study. Our data may indicate the trend toward increasing
resistance in children, which emphasizes the importance of monitoring and
prevention in this population. Fluoroquinolone prophylaxis is rarely provided in
children, which may explain lower rates of fluoroquinolone resistance.
Information about resistance rates and risk factors in auto-HSCT patients is limited
and mainly concerns fluoroquinolones [15, 30], as bacteremia is relatively less
frequent in auto-HSCT patients [31]. Certain factors predisposing to resistant
infections—such as breakthrough bacteremia and prolonged neutropenia—are less
frequent in auto-HSCT vs allo-HSCT patients (Table 2). Although total resistance
rates were higher in allo-HSCT patients, resistance rates in community-acquired
infections were similar. These data reinforce the importance of monitoring
antibiotic susceptibilities in auto-HSCT patients.
Several studies reported risk factors for cephalosporin-resistant, ESBL-producing
or MDR bacteria in cancer and HSCT patients [10, 12, 13, 16, 22, 29, 32]. Only a
handful describe risk factors for carbapenem-resistant infections in populations
involving but not limited to transplant patients, mainly for K. pneumoniae. Distinct
from other studies, we found that breakthrough on noncarbapenems does not
predispose to carbapenem resistance in allo-HSCT patients [8, 14]. Noncarbapenem
β-lactams and carbapenems are both recommended for empiric treatment in febrile
neutropenic patients [25], half of whom have neither microbiological nor clinical
infection. Limitation of carbapenem treatment, de-escalation to a narrower-
spectrum regimen following culture results, and shortening treatment duration, as
recommended by European Conference on Infections in Leukaemia guidelines, will
slow development of carbapenem resistance without increasing mortality [26, 33].
Geographical differences in resistance rates are striking. In certain countries, we
found higher resistance rates than those previously reported in the literature. In
France, for example, 34.4% of GNRs were noncarbapenem resistant, compared with
4% third-generation cephalosporin resistance among Enterobacteriaceae cultured
in hematological malignancies and post-HSCT patients during 2003–2010, which
may be explained by increased resistance rates over time [5]. Information about
resistance rates in each country may, of course, be skewed by local epidemiology of
the participating centers, and not reflective of the situation countrywide. While
carbapenem-resistant GNRs were not reported at all in some countries,
approximately 40% of GNRs were carbapenem resistant in Russia and the Czech
Republic, countries for which existing resistance data are very limited. GNR
resistance rates to carbapenems in other studies, including HSCT patients, varied
from 0% in Sweden [34] to 4.7%–5.8% in the United States [8, 35] to 20.9%, and
even 75.9% among K. pneumoniae, in Italy [7, 11, 14, 27]. Overall, we found
significantly higher resistance rates in southeast as compared with northwest
Europe. This correlates with lower rates of antimicrobial resistance among the
general population [36], which is probably explained by lower consumption of
systemic antibacterials in the community, as well as in veterinary medicine, in
northwest Europe [37, 38].
The multidrug resistance rate (~30%) among Enterobac teriaceae and P. aeruginosa
in our study was within that reported in cancer and HSCT patients [11–13, 35]. The
rate of cotrimoxazole resistance among S. maltophilia, the drug of choice for this
MDR pathogen, was higher in our study (19%) compared to 4%–10% in other
studies [5, 29]. Susceptibility of Acinetobacter species in cancer and transplant
patients has been infrequently studied [5, 29, 39]; XDR Acinetobacter infections were
not previously reported. In our study, a third of Acinetobacter species were XDR.
We demonstrated higher mortality rates in infections caused by resistant bacteria,
similar to other studies [8, 12]. Analysis of mortality risk factors is beyond the scope
of this manuscript.
Our study has limitations. GNR resistance rates and patterns in our study are
influenced by the epidemiology of countries with more participating centers.
Antimicrobial susceptibility data were incomplete for some GNRs. Resistance rates
to certain agents, such as tigecycline, could be overestimated, as susceptibility was
likely checked in bacteria resistant to other treatment options, or reflecting local
epidemiology. We could, however, demonstrate resistance rates to salvage
treatments among their main targets, harder-to-treat pathogens. We did not assess
important risk factors for resistance: history of recent residency in another country
(information unavailable) and prior colonization with resistant GNRs (not all
participating centers performed colonization screening).
The study has important strengths. It is the first intercontinental prospective study
focusing on antimicrobial resistance of GNRs specifically in HSCT patients,
including countries underrepresented in the literature (eg, Russia, Switzerland), and
countries with lower resistance rates, which makes our data more applicable to
large-scale HSCT centers. The large sample size enables unique resistance analysis
in 2 important subgroups—that is, auto-HSCT patients and children, about whom
data in the literature are very scarce. It also allows comparison of data between
auto- and allo-HSCT patients and between children and adults. Contrary to many
studies, we analyze risk factors for different resistance patterns and pathogens,
rather than focusing on specific bacteria or mechanisms.
In conclusion, the problem of antibiotic resistance is worrying in all HSCT patients,
including subgroups of children and auto-HSCT recipients. It is associated with
inappropriate empiric therapy and increased mortality. Benefits of fluoroquinolone
prophylaxis and the approach to empiric therapy should be reassessed and grounded
in continuous monitoring of the local bacteremia rates and susceptibility data of
infecting pathogens. Knowledge of pathogen-specific resistances enables early
appropriate empiric therapy.
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